Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Radiotherapy Planning, Computer-Assisted | 12 | 2023 | 176 | 3.050 |
Why?
|
Radiotherapy, Intensity-Modulated | 14 | 2020 | 173 | 3.040 |
Why?
|
Phantoms, Imaging | 9 | 2020 | 429 | 2.250 |
Why?
|
Thermoluminescent Dosimetry | 3 | 2020 | 5 | 1.820 |
Why?
|
Radiosurgery | 4 | 2020 | 272 | 1.700 |
Why?
|
Organs at Risk | 7 | 2023 | 41 | 1.350 |
Why?
|
Brain Neoplasms | 3 | 2020 | 763 | 1.340 |
Why?
|
Bone Marrow | 6 | 2011 | 435 | 1.330 |
Why?
|
Radiotherapy Dosage | 17 | 2020 | 468 | 1.310 |
Why?
|
Particle Accelerators | 4 | 2020 | 16 | 1.200 |
Why?
|
Tomography, X-Ray Computed | 8 | 2023 | 2601 | 1.050 |
Why?
|
Monte Carlo Method | 4 | 2020 | 185 | 0.990 |
Why?
|
Whole-Body Irradiation | 5 | 2017 | 63 | 0.920 |
Why?
|
Radiotherapy, Conformal | 2 | 2015 | 83 | 0.910 |
Why?
|
Photons | 2 | 2020 | 46 | 0.860 |
Why?
|
Thyroiditis, Subacute | 1 | 2022 | 1 | 0.850 |
Why?
|
Radiation Injuries | 4 | 2015 | 155 | 0.810 |
Why?
|
Beryllium | 1 | 2019 | 1 | 0.740 |
Why?
|
Lung | 3 | 2020 | 1170 | 0.710 |
Why?
|
Bone and Bones | 1 | 2020 | 265 | 0.660 |
Why?
|
Algorithms | 6 | 2020 | 1830 | 0.650 |
Why?
|
Magnetic Resonance Imaging | 3 | 2020 | 3362 | 0.620 |
Why?
|
Uterine Cervical Neoplasms | 4 | 2020 | 275 | 0.600 |
Why?
|
Models, Theoretical | 1 | 2019 | 482 | 0.590 |
Why?
|
Oscillometry | 1 | 2016 | 25 | 0.570 |
Why?
|
Hematologic Neoplasms | 3 | 2023 | 329 | 0.570 |
Why?
|
Transplantation Conditioning | 3 | 2017 | 373 | 0.560 |
Why?
|
Optical Imaging | 1 | 2016 | 48 | 0.540 |
Why?
|
Radiation Dosage | 4 | 2020 | 227 | 0.540 |
Why?
|
Absorption, Radiation | 1 | 2015 | 4 | 0.530 |
Why?
|
Radiotherapy, Computer-Assisted | 1 | 2015 | 25 | 0.530 |
Why?
|
Head | 1 | 2016 | 132 | 0.530 |
Why?
|
Skin Physiological Phenomena | 1 | 2015 | 27 | 0.530 |
Why?
|
Hematologic Diseases | 2 | 2015 | 79 | 0.510 |
Why?
|
Body Burden | 2 | 2012 | 9 | 0.510 |
Why?
|
Respiration | 1 | 2016 | 262 | 0.500 |
Why?
|
Radiometry | 2 | 2012 | 53 | 0.490 |
Why?
|
Models, Chemical | 2 | 2008 | 178 | 0.490 |
Why?
|
Metal Nanoparticles | 2 | 2010 | 30 | 0.470 |
Why?
|
Gold | 2 | 2010 | 41 | 0.470 |
Why?
|
Neoplasms | 3 | 2015 | 2898 | 0.440 |
Why?
|
Whole-Body Counting | 1 | 2012 | 7 | 0.420 |
Why?
|
Imaging, Three-Dimensional | 1 | 2016 | 579 | 0.420 |
Why?
|
Bone Marrow Diseases | 1 | 2012 | 40 | 0.420 |
Why?
|
Deoxyglucose | 1 | 2010 | 37 | 0.380 |
Why?
|
Feasibility Studies | 4 | 2020 | 751 | 0.380 |
Why?
|
X-Ray Microtomography | 1 | 2010 | 80 | 0.370 |
Why?
|
Contrast Media | 3 | 2020 | 1078 | 0.360 |
Why?
|
DNA | 2 | 2008 | 1294 | 0.350 |
Why?
|
Humans | 34 | 2023 | 86643 | 0.340 |
Why?
|
Radiotherapy, Image-Guided | 2 | 2020 | 56 | 0.340 |
Why?
|
Radiation Protection | 1 | 2008 | 25 | 0.330 |
Why?
|
Fiducial Markers | 2 | 2020 | 7 | 0.330 |
Why?
|
Computer Simulation | 4 | 2016 | 1078 | 0.320 |
Why?
|
Pelvic Bones | 1 | 2008 | 44 | 0.320 |
Why?
|
Free Radicals | 1 | 2008 | 73 | 0.320 |
Why?
|
Nucleotides | 1 | 2008 | 95 | 0.310 |
Why?
|
Hematopoietic Stem Cell Transplantation | 3 | 2023 | 878 | 0.310 |
Why?
|
Nitric Oxide | 3 | 2013 | 278 | 0.290 |
Why?
|
DNA Damage | 2 | 2013 | 366 | 0.280 |
Why?
|
Calibration | 2 | 2019 | 99 | 0.260 |
Why?
|
Equipment Design | 2 | 2016 | 406 | 0.250 |
Why?
|
Radiation Injuries, Experimental | 2 | 2015 | 41 | 0.240 |
Why?
|
Endometrial Neoplasms | 1 | 2006 | 193 | 0.230 |
Why?
|
Pulmonary Fibrosis | 2 | 2015 | 123 | 0.220 |
Why?
|
Deoxyribose | 1 | 2002 | 2 | 0.210 |
Why?
|
Chemoradiotherapy | 2 | 2015 | 301 | 0.210 |
Why?
|
Hydroxyl Radical | 1 | 2002 | 35 | 0.210 |
Why?
|
Cell Line, Tumor | 6 | 2018 | 2426 | 0.200 |
Why?
|
Multiple Myeloma | 2 | 2017 | 307 | 0.190 |
Why?
|
Fibrosarcoma | 1 | 2020 | 84 | 0.190 |
Why?
|
Microscopy, Electron, Transmission | 2 | 2010 | 134 | 0.190 |
Why?
|
Saliva | 1 | 2021 | 122 | 0.190 |
Why?
|
Printing, Three-Dimensional | 1 | 2020 | 37 | 0.190 |
Why?
|
Cesium Radioisotopes | 1 | 2019 | 12 | 0.190 |
Why?
|
Cobalt Radioisotopes | 1 | 2019 | 19 | 0.180 |
Why?
|
Oxygen | 3 | 2020 | 726 | 0.180 |
Why?
|
Cell Hypoxia | 1 | 2020 | 164 | 0.170 |
Why?
|
Anus Neoplasms | 2 | 2009 | 30 | 0.160 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2023 | 2438 | 0.160 |
Why?
|
Movement | 1 | 2020 | 299 | 0.150 |
Why?
|
Adult | 9 | 2022 | 25648 | 0.150 |
Why?
|
Adenocarcinoma | 3 | 2013 | 1169 | 0.150 |
Why?
|
Female | 15 | 2022 | 44532 | 0.150 |
Why?
|
Middle Aged | 10 | 2022 | 25028 | 0.140 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2020 | 1204 | 0.140 |
Why?
|
Adaptation, Physiological | 3 | 2013 | 306 | 0.140 |
Why?
|
Rectum | 2 | 2008 | 146 | 0.140 |
Why?
|
Combined Modality Therapy | 5 | 2017 | 1686 | 0.140 |
Why?
|
Motion | 1 | 2016 | 85 | 0.140 |
Why?
|
Receptor, Cannabinoid, CB1 | 1 | 2015 | 11 | 0.140 |
Why?
|
Workflow | 1 | 2016 | 77 | 0.140 |
Why?
|
Reproducibility of Results | 2 | 2015 | 2705 | 0.140 |
Why?
|
Pandemics | 1 | 2022 | 740 | 0.130 |
Why?
|
Software | 1 | 2020 | 654 | 0.130 |
Why?
|
Periodicity | 1 | 2016 | 119 | 0.130 |
Why?
|
Morpholines | 1 | 2015 | 65 | 0.130 |
Why?
|
Aged, 80 and over | 4 | 2022 | 6509 | 0.130 |
Why?
|
Transducers | 1 | 2015 | 41 | 0.130 |
Why?
|
Aged | 7 | 2022 | 18415 | 0.130 |
Why?
|
Urinary Bladder | 2 | 2008 | 246 | 0.130 |
Why?
|
Radiation-Protective Agents | 1 | 2015 | 96 | 0.130 |
Why?
|
Equipment Failure Analysis | 1 | 2015 | 90 | 0.130 |
Why?
|
Pyrazoles | 1 | 2015 | 153 | 0.120 |
Why?
|
Unrelated Donors | 1 | 2014 | 50 | 0.120 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 1 | 2014 | 67 | 0.120 |
Why?
|
Guideline Adherence | 1 | 2015 | 223 | 0.120 |
Why?
|
Lung Neoplasms | 3 | 2015 | 2262 | 0.110 |
Why?
|
Prospective Studies | 1 | 2022 | 4213 | 0.110 |
Why?
|
Serine C-Palmitoyltransferase | 1 | 2012 | 4 | 0.110 |
Why?
|
Fatty Acids, Monounsaturated | 1 | 2012 | 14 | 0.110 |
Why?
|
Phosphotransferases (Alcohol Group Acceptor) | 1 | 2012 | 80 | 0.100 |
Why?
|
Young Adult | 2 | 2022 | 5976 | 0.100 |
Why?
|
Male | 10 | 2022 | 40965 | 0.100 |
Why?
|
Regression Analysis | 2 | 2010 | 596 | 0.100 |
Why?
|
Maximum Tolerated Dose | 2 | 2017 | 270 | 0.100 |
Why?
|
Time Factors | 3 | 2016 | 5210 | 0.100 |
Why?
|
Prognosis | 1 | 2019 | 3679 | 0.100 |
Why?
|
DNA Repair | 1 | 2013 | 356 | 0.100 |
Why?
|
Adolescent | 2 | 2022 | 8981 | 0.100 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2012 | 214 | 0.100 |
Why?
|
Cell Survival | 2 | 2010 | 969 | 0.090 |
Why?
|
Tongue Neoplasms | 1 | 2010 | 50 | 0.090 |
Why?
|
Sensitivity and Specificity | 1 | 2015 | 1991 | 0.090 |
Why?
|
Melphalan | 2 | 2023 | 98 | 0.090 |
Why?
|
Brain | 1 | 2020 | 2216 | 0.090 |
Why?
|
Prostatic Neoplasms | 2 | 2020 | 1721 | 0.090 |
Why?
|
Tumor Stem Cell Assay | 1 | 2009 | 35 | 0.090 |
Why?
|
Tumor Hypoxia | 2 | 2020 | 29 | 0.090 |
Why?
|
Bone Marrow Transplantation | 1 | 2010 | 286 | 0.090 |
Why?
|
Biological Transport | 1 | 2010 | 396 | 0.090 |
Why?
|
Enzyme Inhibitors | 1 | 2012 | 639 | 0.090 |
Why?
|
Radioisotopes | 1 | 2008 | 45 | 0.080 |
Why?
|
Anthropometry | 1 | 2008 | 74 | 0.080 |
Why?
|
Tissue Distribution | 1 | 2008 | 290 | 0.080 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2008 | 188 | 0.080 |
Why?
|
Electron Spin Resonance Spectroscopy | 2 | 2020 | 306 | 0.080 |
Why?
|
Gastrointestinal Tract | 1 | 2009 | 191 | 0.080 |
Why?
|
Forecasting | 1 | 2008 | 304 | 0.080 |
Why?
|
Animals | 5 | 2020 | 26582 | 0.070 |
Why?
|
Water | 1 | 2008 | 277 | 0.070 |
Why?
|
Apoptosis | 1 | 2013 | 1683 | 0.070 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2010 | 375 | 0.070 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2010 | 1076 | 0.070 |
Why?
|
Posture | 1 | 2006 | 125 | 0.070 |
Why?
|
Models, Statistical | 1 | 2010 | 574 | 0.070 |
Why?
|
Intestine, Small | 1 | 2008 | 303 | 0.070 |
Why?
|
Neoplasm Staging | 2 | 2014 | 1939 | 0.070 |
Why?
|
Signal Transduction | 2 | 2013 | 3241 | 0.070 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 1075 | 0.070 |
Why?
|
Brachytherapy | 1 | 2006 | 119 | 0.060 |
Why?
|
Hysterectomy | 1 | 2006 | 146 | 0.060 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2006 | 292 | 0.060 |
Why?
|
Vagina | 1 | 2006 | 161 | 0.060 |
Why?
|
Kaplan-Meier Estimate | 2 | 2018 | 860 | 0.060 |
Why?
|
Infant | 1 | 2010 | 3046 | 0.060 |
Why?
|
Models, Molecular | 1 | 2008 | 1286 | 0.060 |
Why?
|
Nitric Oxide Donors | 2 | 2012 | 12 | 0.050 |
Why?
|
Glutathione S-Transferase pi | 2 | 2012 | 18 | 0.050 |
Why?
|
Hydrogen | 1 | 2002 | 47 | 0.050 |
Why?
|
Stochastic Processes | 1 | 2002 | 74 | 0.050 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2021 | 39 | 0.050 |
Why?
|
Models, Biological | 1 | 2008 | 1749 | 0.050 |
Why?
|
X-Ray Film | 1 | 2020 | 36 | 0.050 |
Why?
|
Proof of Concept Study | 1 | 2020 | 38 | 0.050 |
Why?
|
Polyesters | 1 | 2020 | 41 | 0.050 |
Why?
|
Organ Sparing Treatments | 1 | 2020 | 38 | 0.050 |
Why?
|
Copper | 1 | 2020 | 71 | 0.050 |
Why?
|
Viral Load | 1 | 2021 | 148 | 0.050 |
Why?
|
Nucleic Acid Conformation | 1 | 2002 | 332 | 0.050 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2021 | 273 | 0.050 |
Why?
|
RNA, Viral | 1 | 2021 | 327 | 0.050 |
Why?
|
Retrospective Studies | 4 | 2015 | 8489 | 0.040 |
Why?
|
Up-Regulation | 2 | 2012 | 712 | 0.040 |
Why?
|
Oximetry | 1 | 2020 | 84 | 0.040 |
Why?
|
Mice | 3 | 2020 | 11352 | 0.040 |
Why?
|
Multimodal Imaging | 1 | 2020 | 110 | 0.040 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2012 | 381 | 0.040 |
Why?
|
Child | 1 | 2010 | 6927 | 0.040 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2021 | 879 | 0.040 |
Why?
|
Mitomycin | 2 | 2009 | 29 | 0.040 |
Why?
|
Breast Neoplasms | 1 | 2012 | 2903 | 0.040 |
Why?
|
Pelvis | 2 | 2010 | 95 | 0.040 |
Why?
|
Positron-Emission Tomography | 1 | 2020 | 329 | 0.040 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2020 | 294 | 0.040 |
Why?
|
Retreatment | 1 | 2017 | 107 | 0.040 |
Why?
|
Fluorouracil | 2 | 2009 | 556 | 0.040 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2023 | 1313 | 0.040 |
Why?
|
Transplantation, Autologous | 1 | 2017 | 331 | 0.040 |
Why?
|
Cell Proliferation | 2 | 2012 | 1578 | 0.030 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2015 | 104 | 0.030 |
Why?
|
Radiation Tolerance | 1 | 2015 | 168 | 0.030 |
Why?
|
Myeloablative Agonists | 1 | 2014 | 34 | 0.030 |
Why?
|
Busulfan | 1 | 2014 | 39 | 0.030 |
Why?
|
Recurrence | 1 | 2017 | 1139 | 0.030 |
Why?
|
Gene Deletion | 1 | 2015 | 329 | 0.030 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2017 | 592 | 0.030 |
Why?
|
Survival Analysis | 1 | 2017 | 1538 | 0.030 |
Why?
|
Treatment Outcome | 2 | 2017 | 7993 | 0.030 |
Why?
|
Allografts | 1 | 2014 | 172 | 0.030 |
Why?
|
Immunoblotting | 1 | 2013 | 268 | 0.030 |
Why?
|
Acute Disease | 1 | 2015 | 826 | 0.030 |
Why?
|
Nitric Oxide Synthase | 1 | 2012 | 125 | 0.030 |
Why?
|
Sphingosine | 1 | 2012 | 71 | 0.030 |
Why?
|
Thorax | 1 | 2012 | 75 | 0.030 |
Why?
|
Proportional Hazards Models | 1 | 2014 | 859 | 0.030 |
Why?
|
Longitudinal Studies | 1 | 2015 | 1019 | 0.030 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2013 | 689 | 0.020 |
Why?
|
Comorbidity | 1 | 2015 | 943 | 0.020 |
Why?
|
DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2010 | 3 | 0.020 |
Why?
|
Nitroso Compounds | 1 | 2010 | 12 | 0.020 |
Why?
|
Checkpoint Kinase 1 | 1 | 2010 | 13 | 0.020 |
Why?
|
Nitric Oxide Synthase Type I | 1 | 2010 | 22 | 0.020 |
Why?
|
Checkpoint Kinase 2 | 1 | 2010 | 23 | 0.020 |
Why?
|
X-Rays | 1 | 2010 | 130 | 0.020 |
Why?
|
Incidence | 1 | 2015 | 1577 | 0.020 |
Why?
|
Hemoglobin A | 1 | 2010 | 8 | 0.020 |
Why?
|
Oxidants | 1 | 2010 | 86 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2010 | 303 | 0.020 |
Why?
|
Robotic Surgical Procedures | 1 | 2015 | 267 | 0.020 |
Why?
|
Platelet Count | 1 | 2010 | 92 | 0.020 |
Why?
|
Transforming Growth Factor beta | 1 | 2012 | 301 | 0.020 |
Why?
|
Hydrogen Peroxide | 1 | 2010 | 158 | 0.020 |
Why?
|
Survival Rate | 1 | 2014 | 1863 | 0.020 |
Why?
|
Leukocyte Count | 1 | 2010 | 220 | 0.020 |
Why?
|
Ultraviolet Rays | 1 | 2010 | 193 | 0.020 |
Why?
|
Protein Kinases | 1 | 2010 | 209 | 0.020 |
Why?
|
Probability | 1 | 2010 | 355 | 0.020 |
Why?
|
Blotting, Western | 1 | 2010 | 782 | 0.020 |
Why?
|
Relative Biological Effectiveness | 1 | 2008 | 13 | 0.020 |
Why?
|
Mice, Inbred C57BL | 1 | 2015 | 3092 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2010 | 1041 | 0.020 |
Why?
|
Nuclear Medicine | 1 | 2008 | 12 | 0.020 |
Why?
|
Neutrophils | 1 | 2010 | 307 | 0.020 |
Why?
|
Linear Models | 1 | 2009 | 421 | 0.020 |
Why?
|
Practice Guidelines as Topic | 1 | 2015 | 1036 | 0.020 |
Why?
|
Leukopenia | 1 | 2007 | 65 | 0.020 |
Why?
|
Cisplatin | 1 | 2010 | 612 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2012 | 1197 | 0.020 |
Why?
|
Follow-Up Studies | 1 | 2014 | 3640 | 0.020 |
Why?
|
Neutropenia | 1 | 2007 | 215 | 0.020 |
Why?
|
Anemia | 1 | 2007 | 128 | 0.020 |
Why?
|
Body Mass Index | 1 | 2010 | 770 | 0.020 |
Why?
|
Thrombocytopenia | 1 | 2007 | 183 | 0.020 |
Why?
|
Colonic Neoplasms | 1 | 2009 | 556 | 0.020 |
Why?
|
Risk Factors | 1 | 2015 | 5417 | 0.020 |
Why?
|
Cells, Cultured | 1 | 2009 | 2818 | 0.010 |
Why?
|
United States | 1 | 2015 | 6672 | 0.010 |
Why?
|
Head and Neck Neoplasms | 1 | 2009 | 1052 | 0.010 |
Why?
|
Antineoplastic Agents | 1 | 2010 | 2360 | 0.010 |
Why?
|